- Home
- SLN vs FET Comparison
SLN vs FET Comparison
Compare SLN & FET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- FET
- Stock Information
- Founded
- SLN 1994
- FET 2005
- Country
- SLN United Kingdom
- FET United States
- Employees
- SLN N/A
- FET N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- FET Metal Fabrications
- Sector
- SLN Health Care
- FET Industrials
- Exchange
- SLN Nasdaq
- FET Nasdaq
- Market Cap
- SLN 268.8M
- FET 309.5M
- IPO Year
- SLN N/A
- FET 2012
- Fundamental
- Price
- SLN $4.73
- FET $26.51
- Analyst Decision
- SLN Buy
- FET
- Analyst Count
- SLN 5
- FET 0
- Target Price
- SLN $32.60
- FET N/A
- AVG Volume (30 Days)
- SLN 50.2K
- FET 100.3K
- Earning Date
- SLN 11-13-2025
- FET 10-30-2025
- Dividend Yield
- SLN N/A
- FET N/A
- EPS Growth
- SLN N/A
- FET N/A
- EPS
- SLN N/A
- FET N/A
- Revenue
- SLN $27,169,000.00
- FET $801,867,000.00
- Revenue This Year
- SLN N/A
- FET N/A
- Revenue Next Year
- SLN N/A
- FET $0.45
- P/E Ratio
- SLN N/A
- FET N/A
- Revenue Growth
- SLN 22.28
- FET 3.86
- 52 Week Low
- SLN $1.97
- FET $12.78
- 52 Week High
- SLN $20.48
- FET $27.72
- Technical
- Relative Strength Index (RSI)
- SLN 41.23
- FET 62.88
- Support Level
- SLN $4.77
- FET $25.46
- Resistance Level
- SLN $5.80
- FET $27.72
- Average True Range (ATR)
- SLN 0.36
- FET 0.91
- MACD
- SLN -0.03
- FET -0.07
- Stochastic Oscillator
- SLN 22.46
- FET 61.59
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About FET Forum Energy Technologies Inc.
Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries. The company designs, manufactures, and distributes products and engages in aftermarket parts supply and services that complement its product offering. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. It operates in two reporting segments, namely Drilling and Completions and Artificial Lift and Downhole. Revenue largely comes from Artificial Lift and Downhole segment.